Development of an ELISA for the detection of serum chromogranin A (CgA) inprostate and non-neuroendocrine carcinomas

Authors
Citation
Kc. Tsao et Jt. Wu, Development of an ELISA for the detection of serum chromogranin A (CgA) inprostate and non-neuroendocrine carcinomas, CLIN CHIM A, 313(1-2), 2001, pp. 21-29
Citations number
15
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Medical Research Diagnosis & Treatment
Journal title
CLINICA CHIMICA ACTA
ISSN journal
0009-8981 → ACNP
Volume
313
Issue
1-2
Year of publication
2001
Pages
21 - 29
Database
ISI
SICI code
0009-8981(200111)313:1-2<21:DOAEFT>2.0.ZU;2-R
Abstract
Introduction: Chromogranin A (CgA) is a glycoprotein found in neuroendocrin e cells and may be useful as a tumor marker for neuroendocrine tumors. Meth ods: We developed an enzyme-linked immunosorbent assay (ELISA) for serum Cg A on a microtiter plate. Results: We established a reference range for both women and men of different age groups ranging from 20 to 80 years. Men app eared to have a slightly higher serum CgA concentration than women. This sl ight increase in serum CgA concentration was also found in both gender grou ps with advancing age. We also detected increased serum CgA in a variety of cancers and non-endocrine carcinomas: the majority of the increased serum CgA was associated with specimens containing highly increased concentration of tumor markers. In other words, increased serum CgA was found at later, more advanced stages of the disease in these patients. For patients with pr ostate cancer, serum CgA was increased much earlier than serum PSA in appro ximately one-third of prostate cancer patients developing resistance to hor monal therapy. Conclusions: The early rise of serum CgA provides an early s ignal for prostate cancer patients who developed resistance to hormonal the rapy: this advance signal could create a critical window for therapy change s to be made before diseases progress to a fatal stage. (C) 2001 Elsevier S cience B.V. All rights reserved.